Genmab — Februar 2020
-
Hvis han var kortsigtigt, og kun gik efter kortsigtig gevinst, ville han have fulgt Jørgen Varnæs strategi...
-
Hvis et selskab aflønner med bla. warrants, så bliver bliver disse jo kun til penge hvis selskabet gør det godt..
-
Forøvrigt købte Jan en ordentlig bunke aktier da han lige var blevet CEO. Da tog han en enorm risiko, hvor selskabet blødte og i den grad var truet på livet...
-
Solsen, jo der er en til at man satser kassen på 1BB på dette meget tidlige tidspunkt. THE NEXT WINNER
-
grund til
-
GEN1046
-
DuoBody-PD-L1x4-1BB, one of the products that we are developing along with BioNTech, has the potential to be first-in-class and to provide Genmab with a truly differentiated PD-L1 products. There is a high unmet medical need to improve on checkpoint blockers, and we have seen strong pre-clinical data and encouraging early signs of activity in patients who failed PD-1 and/or PD-L1 checkpoint blockers for DuoBody-PD-L1x4-1BB.
-
God morgen.

-
Live Corona update: https://www.worldometers.info/coronavirus/
-
God morgen.

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind